Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Devimistat (formerly also known as CPI613; CPI 613; CPI-613), a synthetic lipoate analog, is a novel and potent inhibitor of pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase with potential chemopreventive and antineoplastic activities. It disrupts mitochondrial metabolism and shows strong antitumor activity. Devimistat inhibits mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase in NCI-H460 cell line, it disrupts tumor cell mitochondrial metabolism. CPI-613 is developed to target the pyruvate dehydrogenase complex which is a key mitochondrial enzyme of anaerobic glycolysis in tumor cells.
Targets |
Mitochondrial metabolism
|
||
---|---|---|---|
ln Vitro |
GPM-2 stomach cancer cells undergo apoptosis when exposed to devimistat. Devimistat specifically targets a modified version of mitochondrial energy metabolism that tumor cells use. Devimistat causes alterations in the cellular redox state and mitochondrial enzyme activity, which result in cell death, including apoptosis [1].
|
||
ln Vivo |
|
||
Enzyme Assay |
JC-1 analysis for mitochondrial membrane potential (MMP)[2]
MMP was measured by the JC-1 fluorescent probe. CPI-613-treated or non-treated cells were incubated with JC-1 (1:1000 dilution) for 20 min at 37 °C. After PBS washing, cells were observed under a fluorescence microscope with the red fluorescence (550 nm excitation/600 nm emission) and green fluorescence channels (485 nm excitation/535 nm emission). Quantitative analysis of Red/Green fluorescence ratio was measured by NIH ImageJ software. Measurement of ROS levels[2] Intracellular ROS production was determined using the oxidant-sensing fluorescent probe DCFH-DA. Briefly, cells were incubated with 10 μM of DCFH-DA for 20 min at 37 °C and images were captured using a fluorescence microscope. Median fluorescence intensity from at least 100 cells in randomly selected fields were quantified by NIH Image J software as we previously described. |
||
Cell Assay |
Transmission electron microscopy (TEM)[2]
Approximately 1.0 × 107 cells treated with 200 μM CPI-613 or vehicle were fixed with 2% glutaraldehyde in 0.1 M sodium cacodylate (NaCAC) buffer (pH 7.4) for 45 min. The samples were post-fixed in 2% osmium tetroxide in NaCAC, stained with 2% uranyl acetate, dehydrated with a graded ethanol series and embedded in Epon-Araldite resin. Thin sections were cut with a Leica EM UC6 ultramicrotome, collected on copper grids, and stained with uranyl acetate and lead citrate. Cells were observed in a Hitachi HT7700 transmission electron microscope and imaged with an UltraScan 4000 CCD camera and First Light Digital Camera Controller. Three-dimensional (3D) cell culture[2] Briefly, 1 × 105 cells were seeded into 48-well SeedEZ scaffold supplied with complete medium. After 3 days of culture, cells growing in the SeedEZ scaffold were treated with 200 μM CPI-613 for 5 days, and cell viability was measured by alamarBlue at 545/590 nm ex/em, followed by phalloidin staining and imaging as we previously described. Lipolysis analysis[2] Lipid droplets and free fatty acids (FFA) released into the culture medium of pancreatic cancer cells were measured to evaluate lipolysis. AsPC-1 and PANC-1 cells were treated with 200 μM CPI-613 for 48 h prior to lipolysis assessment. To determine lipid droplets, cells were fixed with 4% paraformaldehyde and stained with the dye Oil-Red-O for 30 min using the isopropanol method, followed by processed for haematoxylin staining. The released FFA levels were measured by Free Fatty Acid Quantification Kit according to the manufacturer’s instruction. The absorbance at 570 nm was measured immediately afterwards on a microplate reader. |
||
Animal Protocol |
|
||
References |
[1]. Sakuratani T, et al. Downregulation of ARID1A in gastric cancer cells: a putative protective molecular mechanism against the Harakiri-mediated apoptosis pathway. Virchows Arch. 2021;478(3):401-411.
[2]. CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling. J Exp Clin Cancer Res. 2020; 39: 73. [3]. The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells.Cancers (Basel). 2019 Nov; 11(11): 1678. |
Molecular Formula |
C22H28O2S2
|
---|---|
Molecular Weight |
388.59
|
Exact Mass |
388.15307
|
Elemental Analysis |
C, 68.00; H, 7.26; O, 8.23; S, 16.50
|
CAS # |
95809-78-2
|
Related CAS # |
Devimistat-d10;2586055-61-8
|
Appearance |
White to off-white solid powder
|
LogP |
5.6
|
tPSA |
87.9
|
SMILES |
O=C(O)CCCCC(SCC1=CC=CC=C1)CCSCC2=CC=CC=C2
|
InChi Key |
ZYRLHJIMTROTBO-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24)
|
Chemical Name |
6,8-bis(benzylthio)octanoic acid
|
Synonyms |
CPI613; CPI-613; Devimistat; CPI 613
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 2 mg/mL (5.15 mM) in 2% DMSO + 40% PEG300 + 5% Tween80 + 53% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2 mg/mL (5.15 mM) (saturation unknown) in 2% DMSO 98% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: 1% DMSO+30% polyethylene glycol+1% Tween 80:30 mg/mL |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5734 mL | 12.8670 mL | 25.7341 mL | |
5 mM | 0.5147 mL | 2.5734 mL | 5.1468 mL | |
10 mM | 0.2573 mL | 1.2867 mL | 2.5734 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05926206 | Withdrawn | Drug: Devimistat Drug: Modified FOLFIRINOX |
Metastatic Pancreatic Adenocarcinoma | University of Michigan Rogel Cancer Center |
July 2023 | Phase 1 Phase 2 |
NCT05070104 | Withdrawn | Drug: CPI-613 Drug: modified FFX |
C04.588.274.476.411.307 | Cornerstone Pharmaceuticals | March 30, 2023 | Phase 1 |
NCT05733000 | Recruiting | Procedure: Computed Tomography Drug: Devimistat |
Advanced Biliary Tract Carcinoma Advanced Colorectal Carcinoma |
Northwestern University | March 8, 2023 | Phase 2 |
NCT05325281 | Recruiting | Drug: CPI-613® (Dose level - 1.0 250 mg/m^2) |
Pancreas Adenocarcinoma | Medical College of Wisconsin | October 31, 2022 | Phase 1 |